Cargando…
Tongmai Yangxin intervening in myocardial remodeling after PCI for coronary heart disease: study protocol for a double-blind, randomized controlled trial
BACKGROUND: Coronary heart disease (CHD) has become a common cardiovascular disease that seriously threatens the health of people. As reperfusion in the early phase and drug therapy, especially percutaneous coronary intervention (PCI), have become widely used in the clinic, the mortality of acute my...
Autores principales: | Wang, Yongxia, Wang, Xinlu, Wang, Jianru, Li, Bin, Yu, Rui, Hu, Yucai, Li, Xingyuan, Peng, Guangcao, Zhang, Mengmeng, Zhu, Mingjun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085139/ https://www.ncbi.nlm.nih.gov/pubmed/32197640 http://dx.doi.org/10.1186/s13063-020-4208-4 |
Ejemplares similares
-
Integrating Metabolomics and Network Pharmacology
to Explore the Mechanism of Tongmai Yangxin Pills in Ameliorating
Doxorubicin-Induced Cardiotoxicity
por: Shu, Lexin, et al.
Publicado: (2023) -
Tongmai Yangxin pill alleviates myocardial no-reflow by activating GPER to regulate HIF-1α signaling and downstream potassium channels
por: Chen, Ting, et al.
Publicado: (2023) -
Mechanism of Yangxin Tongmai Decoction in the Treatment of Coronary Heart Disease with Blood Stasis Syndrome Based on Network Pharmacology and Molecular Docking
por: Zhang, Mengxue, et al.
Publicado: (2022) -
Development of a HPLC-MS/MS Method to Determine 11 Bioactive Compounds in Tongmai Yangxin Pill and Application to a Pharmacokinetic Study in Rats
por: Shen, Jiayuan, et al.
Publicado: (2018) -
Tongmai Yangxin Pill combined with metoprolol or metoprolol alone for the treatment of symptomatic premature ventricular complex: a multicenter, randomized, parallel-controlled clinical study
por: LIU, Li-Jun, et al.
Publicado: (2022)